Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Pharnext S.A.. (2/7/17). "Press Release: Pharnext to Present at 2017 BIO CEO & Investor Conference". Paris.

Organisations Organisation Pharnext S.A. (Euronext Paris: ALPHA)
  Organisation 2 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization)
Products Product BIO CEO & Investor Conference 2017 New York
  Product 2 PXT-3003 (Pharnext)
Index terms Index term Pharnext–BIO (US): investor conference, 201702 supply service Pharnext SA presents at BIO CEO & Investor Conference NY
  Index term 2 Pharnext–Stern IR: public relations, 201701 service existent US Investor Relations by Stern IR
Person Person McCabe, Sarah (Stern Investor Relations 201701)
     


Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that company management will present a corporate overview at the 2017 BIO CEO & Investor Conference.

The presentation will take place as follows:
> Date: Monday, February 13th, 2017
> Time: 10:00 am ET (4:00 pm CET)
> Venue: The Waldorf Astoria in New York, New York.

If you are interested in meeting the Pharnext management team during this event, please send an email to Sarah McCabe at sarah@sternir.com


About Pharnext

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

   
Record changed: 2017-07-02

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Pharnext S.A. (Euronext Paris: ALPHA)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px